Caribou Biosciences Announced Clinical Data From CB-010 ANTLER Phase 1 Trial In Second-line LBCL Patients At ASCO 2024; 14.4 Months Median PFS In ANTLER Patients With Partial HLA Matching (≥4 alleles)
Portfolio Pulse from Charles Gross
Caribou Biosciences announced clinical data from its CB-010 ANTLER Phase 1 trial in second-line LBCL patients at ASCO 2024, showing a median progression-free survival (PFS) of 14.4 months in patients with partial HLA matching (≥4 alleles).

June 02, 2024 | 11:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Caribou Biosciences reported positive clinical data from its CB-010 ANTLER Phase 1 trial, showing a median PFS of 14.4 months in second-line LBCL patients with partial HLA matching.
The positive clinical data from the CB-010 ANTLER Phase 1 trial is likely to boost investor confidence in Caribou Biosciences, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100